SEC Form 3 · accession 0001209191-15-039654
aTYR PHARMA INC · LIFE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David M. Weiner
Officer — Chief Medical Officer
Period of report
May 6, 2015
Accepted (ET)
May 6, 2015 · 8:40 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001339970
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | holding | — | — | — | 5,028 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $4.06 | holding | — | — | — | — | Jul 9, 2024 | Common Stock | 115,894 | — | D |
| Stock Option (right to buy)F2 | $9.15 | holding | — | — | — | — | Apr 17, 2025 | Common Stock | 31,430 | — | D |
Explanation of responses
- F11/6th of the shares subject to this option shall vest and become exercisable on March 17, 2015 and the remaining shares subject to this option shall vest in 60 equal monthly installments beginning on March 17, 2015. This option is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer.
- F2The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning on April 17, 2015. This option is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer.
Remarks
Exhibit List Exhibit 24.1 - Power of Attorney